Board of Directors
Mr. Lewin has served on our board of directors since September 2015. He has been a Managing Partner at Crown Predator Holdings since 2000 and has been a private investor since 2000. He has invested across multiple industries, and throughout the capital structure, with a particular focus on companies with innovative technologies and strong intellectual property, including activist situations that require working with management. He has been a director of Halo Maritime Defense Systems, a privately held provider of maritime security product and solutions, since 2007. Mr. Lewin holds a bachelor’s degree in Political Science from Johns Hopkins University.
David Hung, M.D.
Dr. Hung has served on our board of directors since February 2016. He was a co-founder of Medivation, Inc. and served as president, chief executive officer and director of its subsidiary, Medivation Neurology, Inc., from its inception in September 2003 until its acquisition by Medivation in December 2004, at which time he became president, chief executive officer and director of Medivation. Dr. Hung served in those roles until Medivation was acquired by Pfizer, Inc. in September 2016. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of Pro-Duct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung served as a member of the board of directors of Opexa Therapeutics, Inc., a biopharmaceutical company, from May 2006 to October 2011. Dr. Hung received an M.D. from the University of California, San Francisco, School of Medicine, and an A.B. in Biology from Harvard College.
Ms. Colleran has served on our board of directors since November 2015. She served as Global President of LifeCell Corporation from August 2008 to January 2012 after the company was acquired by Kinetic Concepts, Inc. In January 2012, Ms. Colleran was appointed Chief Executive Officer and Director of LifeCell Corporation, a position she held until April 2013. Ms. Colleran originally joined LifeCell in 2002 as the Vice President of Marketing and Business Development and later served as Senior Vice President of Commercial Operations. Prior to joining LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare Corporation in various sales, marketing, business development and general management roles with international experience. She was appointed Vice President, Marketing for Baxter’s U.S. Renal business in 1997 and served in that role until 2001 when she was promoted to Vice President/General Manager of the company’s Renal Pharmaceuticals business. Ms. Colleran received her Bachelor of Science from Molloy College and an M.B.A. from Loyola University of Chicago.
Mr. Schutter has served on our board of directors since January 2016. He has over thirty years of pharmaceutical industry experience and has served as the president and chief executive officer of Arbor Pharmaceuticals, Inc. since April 2010. Prior to joining Arbor Pharmaceuticals, Mr. Schutter served in various roles at Sciele Pharma, Inc., a subsidiary of Shionogi & Co., Ltd., including as president and chief operating officer from 2007 to 2009 and as Vice President of Global Business Development at Solvay S.A. in Basel, Switzerland from 2002 to 2006. He also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. Mr. Schutter began his pharmaceutical career with Reid-Provident Laboratories, Inc., a small entrepreneurial pharmaceutical company based in Atlanta, Georgia. He currently serves on the board of Knight Therapeutics, Inc., Vensun Pharmaceuticals, Inc., a privately held company, Mercer University and Georgia Bio, a privately held company. Mr. Schutter has a degree in Pharmaceutical Sciences from Mercer University and an M.B.A. from Kennesaw State University.
Mr. Condon has served on our board since December 2017. He brings 35 years of experience in the plastic surgery sector, including the breast implant market as President of Mentor Aesthetics from 1990 to 1998. Most recently, Mr. Condon was the CEO and President of Nuvesse Skin Therapies, a venture-backed cosmeceutical skincare company serving the U.S. medical device and retail skin care markets, until its sale to a Korean pharmaceuticals company in 2016. Previous to Nuvesse, he was CEO and President of Merz Aesthetics, Inc. and President and Chief Business Officer of BioForm Medical. BioForm was acquired by Merz Pharma in January 2010. Mr. Condon has also lead other aesthetic companies, acting as CEO of a cosmetic laser company and CEO of a national chain of cosmetic surgery centers. Mr. Condon currently serves on the boards of two other companies in the aesthetic medical field: AirXpanders Inc., a unique breast reconstruction device, and Suneva Medical Inc., which commercializes the longest lasting dermal filler for facial fine lines and wrinkles. Mr. Condon has a BS in Biological Sciences from the University of California, Davis.
Ms. Gersh has served on our board of directors since June 2019. Most recently, Ms. Gersh served as the Chief Executive Officer of Alexander Wang, the global fashion brand, from October 2017 to October 2018. Prior to Alexander Wang, Ms. Gersh served as Chief Executive Officer of Goop, Inc. (2014-2016), Gwyneth Paltrow’s lifestyle publication, and as the President and Chief Executive Officer of Martha Stewart Living Omnimedia, Inc. (2012-2013). Ms. Gersh has served as a director of Hasbro, Inc. since 2010. Additionally, Ms. Gersh was a Co-founder of Oxygen Media (1998-2007) and President of Strategic Initiatives at NBCUniversal (2007-2011), where she was responsible for the creation of critical partnerships and initiatives, as well as day-to-day operations. Ms. Gersh was admitted to the New York State Bar in 1984, after earning her J.D. from Rutgers Law School, and holds a Bachelor’s degree in Political Science and Economics from SUNY Binghamton.
Juan José Chacón-Quirós
CEO & Founder
Mr. Chacón-Quirós founded Establishment Labs in 2004, and has been a Director and Chief Executive Officer of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chacón Quirós has been involved in several sectors of the aesthetics industry, including serving for almost a decade as General Manager of an aesthetic medical device distribution business in Latin America and prior to that as Business Development Manager of a renowned plastic and reconstructive surgery clinic in Costa Rica. He has co-authored more than 45 patents that are helping advance the technology in areas like implants and surfaces, RFID and biosensors, 3D technology and surgical instruments development. He served as President of the Rugby Federation of Costa Rica from 2009 to 2015. Mr. Chacón-Quirós received his undergraduate degree from the Academie de Poitiers (economics) and attended the University of Massachusetts at Amherst. He holds the MIT Sloan Advanced Certificate for Executives (ACE) in Management, Innovation and Technology.